Employees: 11-50
Total raised: $19M
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.03.2021 | - | $13M | Takeda Ven... |
| 17.07.2018 | Series D | $6M | - |
Mentions in press and media 13
| Date | Title | Description |
| 03.03.2021 | Presage Closes $13M Financing Round | Presage Biosciences, Inc., a Seattle, WA-based biotechnology company pioneering a new cancer drug development approach using its Comparative In Vivo Oncology (CIVO®) intratumoral microdosing platform, closed a $13m financing and commenced n... |
| 02.03.2021 | Presage Biosciences raises $13M and inks new deal with Merck for cancer drug tests | Presage CEO Richard Klinghoffer. (Presage Photo) New funds, new partners: Seattle’s Presage Biosciences announced $13 million in funding as well new collaborations with biotech giant Merck and California-based Maverick Therapeutics. Presage... |
| 02.03.2021 | Presage Biosciences, Inc. announced that it has received $13 million in funding from Takeda Ventures, Inc., Labcorp Ventures, Bristol-Myers Squibb Company, InHarv Partners Ltd. | Presage Biosciences, Inc. announced that it has issued a convertible note for gross proceeds of $6,000,000 and equity for gross proceeds of $7,000,000 in a round of funding on March 2, 2021. The transaction includes participation from exist... |
| 02.03.2021 | Presage Biosciences, Inc. announced that it has received $7 million in funding from InHarv Partners Ltd., Bristol-Myers Squibb Company, Labcorp Ventures | On March 2, 2021, Presage Biosciences, Inc. closed the transaction. The company received $7,000,000 from new investors Labcorp Ventures, Bristol-Myers Squibb Company and InHarv Partners Ltd. The round was raised at post money valuation of $... |
| 18.07.2018 | Presage Biosciences Closes $6M Series D Financing | Presage Biosciences, a Seattle, WA-based cancer biotechnology company advancing the use of intratumoral microdosing for Phase 0 investigation of early development candidates, closed a $6M Series D financing. The round was led by pharmaceuti... |
| 17.07.2018 | Presage Biosciences raises $6M for technology to test new cancer drugs, appoints new CEO | Rich Klinghoffer first joined Presage as the company’s chief science officer and its second employee. He was appointed its CEO Tuesday. (Photo courtesy of Presage Biosciences) Cancer technology maker Presage Biosciences has raised $6 millio... |
| 20.08.2015 | Presage Biosciences Receives Strategic Investment from Takeda | Presage Biosciences, a Seattle, WA-based oncology company advancing a drug development approach that incorporates human efficacy data much earlier in development and clinical trials, secured a strategic investment from Takeda Pharmaceutical... |
| 09.01.2014 | Avelas’ luminous mapping technology to guide breast cancer surgery attracts $6.85M | Avalon Ventures led the round and new investors Torrey Pines Investment, WuXi AppTec and an unnamed investor also took part. One advantage of Avelas’ platform is that it can help surgeons evaluate tumor samples in real-time. According to th... |
| 03.12.2013 | Imaging agent that ‘paints’ tumor cells for more precise removal nets $9M for clinical trials | In the video above, Blaze Bioscience’s scientific founder, Dr. James Olson, describes how the scorpion-derived protein “happens to bind to cancer cells, but not to normal tissues.” A team from the Fred Hutchinson Cancer Research Center and ... |
| 21.03.2013 | Celgene deal boosts startup developing a way to test different cancer drugs in the same tumor | Under the deal, Celgene will use Presage’s technology for preclinical screening of cancer drug candidates. The platform technology enables researchers to place multiple “threads” of potential treatments into a living tumor and compare side-... |
Show more